Cell-Based High-Throughput Screening Assay System for Monitoring G Protein-Coupled Receptor Activation Using β-Galactosidase Enzyme Complementation Technology
Free accessOtherFirst published online October, 2002
Cell-Based High-Throughput Screening Assay System for Monitoring G Protein-Coupled Receptor Activation Using β-Galactosidase Enzyme Complementation Technology
A novel cell-based functional assay to directly monitor G protein-coupled receptor (GPCR) activation in a high-throughput format, based on a common GPCR regulation mechanism, the interaction between β-arrestin and ligand-activated GPCR, is described. A protein-protein interaction technology, the InteraX™ system, uses a pair of inactive β-galactosidase (β-gal) deletion mutants as fusion partners to the protein targets of interest. To monitor GPCR activation, stable cell lines expressing both GPCR- and β-arrestin-β-gal fusion proteins are generated. Following ligand stimulation, β-arrestin binds to the activated GPCR, and this interaction drives functional complementation of the β-gal mutant fragments. GPCR activation is measured directly by quantitating restored β-gal activity. The authors have validated this assay system with two functionally divergent GPCRs: the β2-adrenergic amine receptor and the CXCR2 chemokine-binding receptor. Both receptors are activated or blocked with known agonists and antagonists in a dose-dependent manner. The β2-adrenergic receptor cell line was screened with the LOPAC™ compound library to identify both agonists and antagonists, validating this system for high-throughput screening performance in a 96-well microplate format. Hit specificity was confirmed by quantitating the level of cAMP. This assay system has also been performed in a high-density (384-well) microplate format. This system provides a specific, sensitive, and robust methodology for studying and screening GPCR-mediated signaling pathways.
References
1.
1. Rossi F, Charlton CA, Blau HM: Monitoring protein-protein interactions in intact eukaryotic cells by β-galactosidase complementation. Proc Natl Acad Sci USA1997;94:8405-8410.
2.
2. Rossi FMV, Blakely BT, Blau HM: Interaction blues: protein interactions monitored in live mammalian cells by β-galactosidase complementation. Trends Cell Biol2000;10:119-122.
3.
3. Blakely BT, Rossi FMV, Tillotson B, Palmer M, Estelles A, Blau HM: Epidermal growth factor receptor dimerization monitored in live cells. Nature Biotech2000;18:218-222.
4.
4. Mohler WA, Blau HM: Gene expression and cell fusion analyzed by lacZ complementation in mammalian cells. Proc Natl Acad Sci USA1996;93:12423-12427.
5.
5. Mundell SJ, Loudon RB, Benovic JL: Characterization of G protein-coupled receptor regulation in antisense mRNA-expressing cells with reduced arrestin levels. Biochemistry1999;38:8723-8732.
6.
6. Ferguson SSG, Downey WE III, Colapietrok AM, et al: Role of β-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science1996;274:363-366.
7.
7. Ferguson SSG: Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacological Reviews2001;53:1-24.
8.
8. Oakley RH, Laporte SA, Holt JA, et al: Association of β-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J Biol Chem1999;274:32248-32257.
9.
9. Lohse MM, Benovic JL, Codina J, et al: β-arrestin: a protein that regulates β-adrenergic receptor function. Science1990;248:1547-1550.
10.
10. Lohse MM, Andexinger S, Pitcher J, et al: Receptor-specific desensitization with purified proteins: kinase dependence and receptor specificity of β-arrestin and arrestin in the β2-adrenergic and rhodopsin systems. J Biol Chem1992;267:85558-85564.
12. Penn RB, Benovic JL: Regulation of G Protein-Coupled Receptors. In: Conn PM, editor. Handbook of physiology. Vol. 1. New York: Oxford University Press,1998. p 125-164.
13.
13. Krupnick JG, Gurevich VV, Benovic JL: Mechanisms of quenching of phototransduction: binding competition between arrestin and transducin for phosphorhodopsin. J Biol Chem1997;272:18125-18131.
14.
14. Kuhn H, Hall SW, Wilden U: Light-induced binding of 48-kDa protein to photoreceptor membranes is highly enhanced by phosphorylation of rhodopsin. FEBS Lett1984;176:473-478.
15.
15. Wilden U, Hall SW, Kuhn H: Phosphodiesterase activation by photoexcited rhodopsin is quenched when rhodopsin is phosphorylated and binds the intrinsic 48-kDa protein of rod outer segments. Proc Natl Acad Sci USA1986;83:1174-1178.
16.
16. Attramadal H, Arriza JL, Aoki C, et al: β-Arrestin 2, a novel member of the arrestin/β-arrestin gene family. J Biol Chem1992;267:17882-17890.
17.
17. Pippig S, Andexinger S, Daniel K, et al: Over-expression of β-arrestin and β-adrenergic receptor kinase augment desensitization of β2-adrenergic receptor. J Biol Chem1993;268:3201-3208.
18.
18. Sterne-Marr R, Gurevich VV, Goldsmith P, et al: Polypeptide variants of β-arrestin and arrestin3. J Biol Chem1993;268:15640-15648.
19.
19. Barak LS, Ferguson SSG, Zhang J, et al: A β-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem1997;272:27497-27500.
20.
20. Zhang J, Barak LS, Anborgh PH, et al: Cellular trafficking of G protein- coupled receptor β-arrestin endocytic complexes. J Biol Chem1999;274:10999-10006.
21.
21. Angers S, Salahpour A, Joly E, et al: Detection of β2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci USA2000;97:3684-3689.
22.
22. Hieble JP: Drugs targeting adrenergic receptors: does interaction with a specific subtype confer therapeutic advantage? Curr Opin Drug Disc Dev2000;3:370-382.
23.
23. Ahuja SK, Murphy PM: The CXC chemokines growth-regulated oncogene (GRO)α, GRO β, GRO γ, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem1996;271:20545-20550.
24.
24. Jones SA, Dewald B, Clark-Lewis I, et al: Chemokine antagonists that discriminate between interleukin-8 receptors. J Biol Chem1997;26:16166-16169.
25.
25. Graham DL, Bevan N, Lowe PN, et al: Application of β-galactosidase enzyme complementation technology as a high throughput screening format for inhibitors of the epidermal growth factor receptor. J Biomol Screen2001;6:401-411.
26.
26. Chiulli AC, Trompeter K, Palmer M: A novel high throughput chemiluminescent assay for the measurement of cellular cyclic adenosine monophosphate levels. J Biomol Screen2000;5:239-247.
27.
27. Ferguson SSG, Menard L, Barak LS, et al: Role of phosphorylation in agonist-promoted β -adrenergic receptor sequestration. J Biol Chem1995;270:24782-24789.
28.
28. Mouillac B, Caron M, Bonin H, et al: Agonist-modulated palmitoylation of the β -adrenergic receptor in Sf9 cells. J Biol Chem1992;267:21733-21737.
29.
29. Fan GH, Yang W, Wang XJ, et al: Identification of a motif in the carboxyl terminus of CXCR2 that is involved in adaptin 2 binding and receptor internalization. Biochemistry2001;40:791-800.
30.
30. Prado GN, Suzuki H, Wilkinson N, et al: Role of the C terminus of the interleukin 8 receptor in signal transduction and internalization. J Biol Chem1996;271:19186-19190.
31.
31. White JR, Lee JM, Young PR, et al: Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem1998;273:10095-10098.
32.
32. Zhang JH, Chung TDY, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen1999;4:67-73.
